Pub Date : 2021-12-01DOI: 10.52927/jdcr.2021.9.2.75
J. Choe
createctomy to treat T2N1M0 pancreatic tail cancer. After six weeks of surgery, the patient’s general condition was good, and a total of six cycles of primary adjuvant chemotherapy with 5-fluorouracil (5-FU) (425 mg/m) and folic acid (20 mg/m) every four weeks was planned. After the end of the third cycle of chemotherapy, the patient visited the emergency room with epigastric pain and mild fever. The blood tests revealed 635 IU/L amylase and 559 IU/L lipase. The other laboratory results were within the normal ranges. Abdominal computed tomography (CT) revealed fluid collection at the pancreatic resection margin with diffuse mesenteric and omental infiltration in the pericolic (hepatic flexure colon, transverse colon), perigastric, and periduodenal regions (Fig. 1). There was no evidence of postoperative leakage of pancreatic juice, recurring pancreatic cancer, or gallstones. He had not taken any over-the-counter drugs and had no history of alcohol consumption or other risk factors commonly associated with pancreatitis. The diagnosis of acute pancreatitis was made without a definite etiology. During the next two weeks, he received conservative care and bowel rest with intravenous hydration. The complaint symptoms were diminished and pancreatic enzyme levels were also normalized. He was discharged from the hospital and planned to be admitted again on his next scheduled chemotherapy day. However, a recurrent pancreatitis episode occurred two days following the completion of the 5-FU infusion in the next (fourth) cycle. At that time, severe abdominal pain persisted, and the serum amylase and lipase levels had increased to 419 IU/L and 393 IU/L, respectively. A CT scan was performed and revealed that inflammatory infiltration into the mesentery and omentum had progressed more extensively than in the previous examination. Multiple large pseudocysts were observed around the pancreas (Fig. 2). However, the cause of recurrent pancreatitis was not clearly determined in the CT scan or the following magnetic resonance imaging. All the possible common causes of acute pancreatitis were excluded. Moreover, considering the relationship between the time of administration of the chemotherapeutic agents and the recurrence of pancreatitis follow-
{"title":"An Unusual Cause of Acute Pancreatitis","authors":"J. Choe","doi":"10.52927/jdcr.2021.9.2.75","DOIUrl":"https://doi.org/10.52927/jdcr.2021.9.2.75","url":null,"abstract":"createctomy to treat T2N1M0 pancreatic tail cancer. After six weeks of surgery, the patient’s general condition was good, and a total of six cycles of primary adjuvant chemotherapy with 5-fluorouracil (5-FU) (425 mg/m) and folic acid (20 mg/m) every four weeks was planned. After the end of the third cycle of chemotherapy, the patient visited the emergency room with epigastric pain and mild fever. The blood tests revealed 635 IU/L amylase and 559 IU/L lipase. The other laboratory results were within the normal ranges. Abdominal computed tomography (CT) revealed fluid collection at the pancreatic resection margin with diffuse mesenteric and omental infiltration in the pericolic (hepatic flexure colon, transverse colon), perigastric, and periduodenal regions (Fig. 1). There was no evidence of postoperative leakage of pancreatic juice, recurring pancreatic cancer, or gallstones. He had not taken any over-the-counter drugs and had no history of alcohol consumption or other risk factors commonly associated with pancreatitis. The diagnosis of acute pancreatitis was made without a definite etiology. During the next two weeks, he received conservative care and bowel rest with intravenous hydration. The complaint symptoms were diminished and pancreatic enzyme levels were also normalized. He was discharged from the hospital and planned to be admitted again on his next scheduled chemotherapy day. However, a recurrent pancreatitis episode occurred two days following the completion of the 5-FU infusion in the next (fourth) cycle. At that time, severe abdominal pain persisted, and the serum amylase and lipase levels had increased to 419 IU/L and 393 IU/L, respectively. A CT scan was performed and revealed that inflammatory infiltration into the mesentery and omentum had progressed more extensively than in the previous examination. Multiple large pseudocysts were observed around the pancreas (Fig. 2). However, the cause of recurrent pancreatitis was not clearly determined in the CT scan or the following magnetic resonance imaging. All the possible common causes of acute pancreatitis were excluded. Moreover, considering the relationship between the time of administration of the chemotherapeutic agents and the recurrence of pancreatitis follow-","PeriodicalId":90588,"journal":{"name":"Journal of digestive cancer reports","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42484717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.52927/jdcr.2021.9.2.50
Dong-Hoon Yang
{"title":"Recent Advance in the Management of Dysplasia in the Ulcerative Colitis","authors":"Dong-Hoon Yang","doi":"10.52927/jdcr.2021.9.2.50","DOIUrl":"https://doi.org/10.52927/jdcr.2021.9.2.50","url":null,"abstract":"","PeriodicalId":90588,"journal":{"name":"Journal of digestive cancer reports","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45508156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.52927/jdcr.2021.9.2.57
Eun Soo Kim
{"title":"Update of Korean Standard Classification of Diseases for Rectal Carcinoid and Its Clinical Implication","authors":"Eun Soo Kim","doi":"10.52927/jdcr.2021.9.2.57","DOIUrl":"https://doi.org/10.52927/jdcr.2021.9.2.57","url":null,"abstract":"","PeriodicalId":90588,"journal":{"name":"Journal of digestive cancer reports","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49517816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.52927/jdcr.2021.9.2.43
Eun Ju Choe, Yong Kang Lee, H. Jeon, Jongwon Choi, B. Park, S. Won, J. Seo, C. Lee, Yong Suk Cho
{"title":"Postoperative Clinical Outcomes of Colonic Stent Placement as Bridge-to-surgery vs. Emergency Surgery in Left-sided Malignant Colonic Obstruction","authors":"Eun Ju Choe, Yong Kang Lee, H. Jeon, Jongwon Choi, B. Park, S. Won, J. Seo, C. Lee, Yong Suk Cho","doi":"10.52927/jdcr.2021.9.2.43","DOIUrl":"https://doi.org/10.52927/jdcr.2021.9.2.43","url":null,"abstract":"","PeriodicalId":90588,"journal":{"name":"Journal of digestive cancer reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41774677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.52927/jdcr.2021.9.2.60
S. Kim, Ji Won Kim
Tumors of the small intestine are rare and generally asymptomatic or with nonspecific symp-toms. The small intestine is difficult to approach using conventional endoscopy, and early diagnosis of the small intestinal tumors is difficult. Therefore, many of the small intestinal tumors are diagnosed at an advanced stage, which makes the prognosis poor. Premalignant lesions of the small intestine or known risk factors of small bowel cancer are sporadic adenoma, adenoma associated with familial adenomatous polyposis, hamartomatous polyp associated with Peutz-Jeghers syndrome, Crohn’s disease, and celiac disease. Therefore, it is necessary to recognize that the small bowel cancer can occur in these patients with premalignant lesions or risk factors of small bowel cancer. To reduce the possibility of small bowel cancer or to detect at an earlier stage, attention should be paid to screening and surveillance of these patients with premalignant lesions or risk factors of the small bowel cancer.
{"title":"Premalignant Lesions of the Small Intestine","authors":"S. Kim, Ji Won Kim","doi":"10.52927/jdcr.2021.9.2.60","DOIUrl":"https://doi.org/10.52927/jdcr.2021.9.2.60","url":null,"abstract":"Tumors of the small intestine are rare and generally asymptomatic or with nonspecific symp-toms. The small intestine is difficult to approach using conventional endoscopy, and early diagnosis of the small intestinal tumors is difficult. Therefore, many of the small intestinal tumors are diagnosed at an advanced stage, which makes the prognosis poor. Premalignant lesions of the small intestine or known risk factors of small bowel cancer are sporadic adenoma, adenoma associated with familial adenomatous polyposis, hamartomatous polyp associated with Peutz-Jeghers syndrome, Crohn’s disease, and celiac disease. Therefore, it is necessary to recognize that the small bowel cancer can occur in these patients with premalignant lesions or risk factors of small bowel cancer. To reduce the possibility of small bowel cancer or to detect at an earlier stage, attention should be paid to screening and surveillance of these patients with premalignant lesions or risk factors of the small bowel cancer.","PeriodicalId":90588,"journal":{"name":"Journal of digestive cancer reports","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49386538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.52927/jdcr.2021.9.2.71
J. Cheon
{"title":"Immune Checkpoint Inhibitors in Advanced Colorectal Cancer","authors":"J. Cheon","doi":"10.52927/jdcr.2021.9.2.71","DOIUrl":"https://doi.org/10.52927/jdcr.2021.9.2.71","url":null,"abstract":"","PeriodicalId":90588,"journal":{"name":"Journal of digestive cancer reports","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42760972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.52927/jdcr.2021.9.2.68
Sojung Han, Jun Yong Kim, Jae Jun Park
{"title":"Multiple Rectal Neuroendocrine Tumor","authors":"Sojung Han, Jun Yong Kim, Jae Jun Park","doi":"10.52927/jdcr.2021.9.2.68","DOIUrl":"https://doi.org/10.52927/jdcr.2021.9.2.68","url":null,"abstract":"","PeriodicalId":90588,"journal":{"name":"Journal of digestive cancer reports","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48812653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Competency for practicing gastroenterology in the United States requires accredited training in Internal Medicine, followed by accredited training in gastroenterology and hepatology. The structured training encompasses a 3-year period after graduation with a medical degree for internal medicine, followed by a 3-year period for gastroenterology and hepatology. Within the gastroenterology training period, competency in oncology knowledge and procedural approaches to luminal and solid gastrointestinal organ cancers is required, whereas knowledge competency but not procedural competency is required in areas of advanced endoscopic procedures for cancer care. Only general knowledge, but not competency, is required for areas such as chemotherapy, which can be obtained with further optional training in a structured 2-year oncology fellowship program. Although there is no standardization to date for including full oncology training within a gastroenterology training program in the United States, there is great interest from gastroenterology professional societies to include a pathway for trainees within the gastroenterology training program.
{"title":"The United States System for Training of Gastroenterologists in Oncology.","authors":"John M Carethers","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Competency for practicing gastroenterology in the United States requires accredited training in Internal Medicine, followed by accredited training in gastroenterology and hepatology. The structured training encompasses a 3-year period after graduation with a medical degree for internal medicine, followed by a 3-year period for gastroenterology and hepatology. Within the gastroenterology training period, competency in oncology knowledge and procedural approaches to luminal and solid gastrointestinal organ cancers is required, whereas knowledge competency but not procedural competency is required in areas of advanced endoscopic procedures for cancer care. Only general knowledge, but not competency, is required for areas such as chemotherapy, which can be obtained with further optional training in a structured 2-year oncology fellowship program. Although there is no standardization to date for including full oncology training within a gastroenterology training program in the United States, there is great interest from gastroenterology professional societies to include a pathway for trainees within the gastroenterology training program.</p>","PeriodicalId":90588,"journal":{"name":"Journal of digestive cancer reports","volume":"2 1","pages":"11-14"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288825/pdf/nihms643570.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32970502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
With advances in technology, advances in the understanding of biology of cancer, and the advent of improved and novel therapies, the role of the gastroenterologist has been modified greatly over the past 2 decades, and continues to be shaped by the knowledge, skill, and opportunity to capitalize on the unique position that gastroenterologists hold in the patient care continuum. The gastroenterologist is evolving from a "pure" diagnostician to an endoscopic surgeon, a geneticist, a nutritionist, an immunologist and chemotherapist, and palliative care physician.
{"title":"Current and Future Role of the Gastroenterologist in GI Cancer Management.","authors":"John M Carethers","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>With advances in technology, advances in the understanding of biology of cancer, and the advent of improved and novel therapies, the role of the gastroenterologist has been modified greatly over the past 2 decades, and continues to be shaped by the knowledge, skill, and opportunity to capitalize on the unique position that gastroenterologists hold in the patient care continuum. The gastroenterologist is evolving from a \"pure\" diagnostician to an endoscopic surgeon, a geneticist, a nutritionist, an immunologist and chemotherapist, and palliative care physician.</p>","PeriodicalId":90588,"journal":{"name":"Journal of digestive cancer reports","volume":"1 2","pages":"78-81"},"PeriodicalIF":0.0,"publicationDate":"2013-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262247/pdf/nihms608412.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32907463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：